Clinical Trials Logo

Clinical Trial Summary

This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study. And the independent review committee (IRC) will be formed to monitor efficacy data through the study.


Clinical Trial Description

The efficacy and safety of Yttrium-90 carbon microspheres in patients with unresectable LAPC remain unknown. This trial is a prospective, multicenter, open-label, single-arm phase I trial designed to evaluate the safety and efficacy of NRT6008 injection. The primary objective is to evaluate the safety of NRT6008 Injection. While the secondary objectives include the assessments of the preliminary efficacy. In addition, the distribution of NRT6008 injection in human body, and the changes of tumor biomarkers and the improvement of cancer pain status of participants after administration will also be evaluated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06278454
Study type Interventional
Source Chengdu New Radiomedicine Technology Co. LTD.
Contact Zhaoshen Li
Phone +8602131162338
Email zhsl@vip.163.com
Status Not yet recruiting
Phase Phase 1
Start date March 2024
Completion date December 2026

See also
  Status Clinical Trial Phase
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06026943 - Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer N/A
Not yet recruiting NCT02945267 - Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer Phase 4
Completed NCT01304160 - Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer Phase 1/Phase 2
Withdrawn NCT05251038 - Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer Phase 1/Phase 2
Completed NCT03602885 - EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options N/A
Completed NCT03239184 - Bioinformation Therapy for Pancreatic Cancer Phase 2/Phase 3
Recruiting NCT04002479 - Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer N/A
Recruiting NCT03063554 - EUS BD vs ERCP TP for Pancreatic Cancer N/A
Completed NCT03250273 - A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Phase 2
Not yet recruiting NCT06099119 - Efficacy of PERT for PEI in Unresectable Pancreatic Cancer. Phase 4
Completed NCT02035072 - Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer. Phase 2
Terminated NCT04698915 - Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer Phase 2
Recruiting NCT04789486 - Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer Phase 1/Phase 2
Active, not recruiting NCT03138720 - Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Phase 2
Active, not recruiting NCT04395469 - FAZA PET/MRI Pancreas N/A
Recruiting NCT04093141 - Chemotherapy Followed by Irreversible Electroporation in Patients With Unresectable Locally Advanced Pancreatic Cancer N/A
Terminated NCT02166190 - RFA RCT for Pancreatic or Bile Duct Cancer N/A
Completed NCT02282722 - Improving Informed Consent for Palliative Chemotherapy N/A
Recruiting NCT05601323 - A Study of Suizenji in Patients With Unresectable Pancreatic Cancer N/A